Le Lézard
Classified in: Health, Science and technology
Subject: PER

GATC Health engages Dr. Chad Beyer to head IND-enabling studies for its AI-generated Opioid Use Disorder drug candidate


An addiction medicine expert with more than 30 IND filings and two FDA successes, Dr. Beyer will help to advance GATC compounds to human clinical trials.

IRVINE, Calif., May 30, 2024 /PRNewswire/ -- GATC Health Corp, a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), has engaged GATC advisor Dr. Chad Beyer to oversee FDA Investigative New Drug (IND)-enabling studies to advance GATC compounds to human clinical trials.

Dr. Beyer has significant experience in obtaining INDs and the regulatory pathway in the addiction space and he will augment the company's current research to secure FDA approval to enter phase one clinical trials for this AI-generated OUD asset. Dr. Beyer has served as a member of GATC's Board of Advisors since January 2022 and is a pharmaceutical executive with an expertise in addiction medicine and more than two decades of experience in the biopharmaceutical industry.

"The preclinical data from GATC's OUD candidate demonstrates the compound could be a powerful solution to turn around this deady epidemic," said Dr. Beyer. "Through its AI platform, GATC has uncovered multiple targets along with a novel compound that have tested extremely well for effectiveness and safety. I am excited to consult with the team to advance this promising set of medications toward human trials," added Dr. Beyer.

"Chad has served on our advisory board as a valued expert in addiction medicine, with a substantial history in achieving the types of regulatory milestones we are seeking with our OUD asset," said Ian Jenkins, Chief Science Officer at GATC. "Buoyed by the results of our recent animal trials on this drug candidate at University of California, Irvine, we are ready to leverage Chad's extensive drug development expertise to help complete the IND-enabling work for this asset. Once approved, we will be ready to seek a development partner for this exciting new non-opioid approach to combating addiction," added. Mr. Jenkins.

Professional biography of Dr. Beyer:
Dr. Beyer has a successful track record of building, leading and working with high-performing cross-functional teams ranging from preclinical to clinical to regulatory to CMC to BD domains. He has worked across the industry from bench scientist to Head of Neurochemistry and has participated in the submission of more than 30 INDs and operationalized more than 10 Phase 1 / Phase 2 studies. Dr. Beyer began his career at Wyeth Pharmaceuticals after completing an internship at the National Institute on Drug Abuse (NIDA) and is currently COO at Channavix. He holds a Ph.D. in Pharmacology & Toxicology from LSU Medical Center and an MBA in Pharmaceutical Management from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, co-edited 2 books, and has served on the Board of Directors and Scientific Advisory Board of several private companies. 

About GATC Health
GATC Health Corp?is a technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which de-risks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency and speed never before achieved in medical science. The company's validated and proprietary Multiomics Advanced Technologytm (MAT) platform simulates human biochemistry's billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC envisions the future of medicine now, where health is protected, disease is reversed, and every person's unique biology is treated with precision.

SOURCE GATC Health Corp


These press releases may also interest you

at 19:35
IGC Pharma, Inc. ("IGC" or the "Company") , a clinical-stage pharmaceutical company, has announced its financial results for the fiscal year ended March 31, 2024 ("Fiscal 2024"). Full Fiscal Year Highlights In March 2024, the Company announced...

at 19:05
OPEX® Corporation, a global leader in Next Generation Automation providing solutions for document, mail, and warehouse automation, has announced the planned first installation of the company's Perfect Pick HD® automated storage and retrieval system...

at 19:01
Almost half (45%) of workers say their workload has increased significantly in the past year, as almost two-thirds (62%) say the pace of change at work has increased over the same timeMore than one-quarter (28%) say they are very or extremely likely...

at 18:44
Fairness for every generation means making sure everyone in Canada has access to reliable and affordable high-speed Internet, no matter where they live. That is why the governments of Canada and Ontario are bringing high-speed Internet access to...

at 18:38
Amagi, the global leader in cloud-based SaaS technology for broadcast and Connected TV (CTV), today announced the first successful showcase of Amagi's Zero Slate technology on VIZIO's owned and operated WatchFree+ channels, part of Amagi's broader...

at 18:36
Across the country, Canadians are looking to live in sustainable communities: places with clean air, affordable homes and good employment opportunities. Building sustainable communities means that as a federal government, we are continually investing...



News published on and distributed by: